Click here to register for this event
Date: February 13, 2019
Location: Boehringer Ingelheim Campus
900 Ridgebury Rd, Ridgefield, CT 06877
This one-of-a-kind symposium will focus on key considerations for transitioning a molecule from discovery to clinic including API and formulation development, pharmacokinetics, quality and CMC requirements, and incorporation of patient focus design principles. The agenda is designed to be highly interactive with activities designed for the audience to work in teams to apply the principles from the presentations and ample time for networking.
Agenda:
8:00 am – 8:30 am | WELCOME & INTRODUCTION
Dr. Keith Horspool, VP, Pharmaceutics, Boehringer Ingelheim
Dr. Cornell Stamoran, Founder, Catalent Institute
8:30 am – 9:05 am | IMPORTANCE OF API CHARACTERIZATION FOR IMPROVING DEVELOPABILITY OF SMALL MOLECULES
Dr. Fredrik Nordstrom, Sr. Principal Scientist, Boehringer Ingelheim
9:05 am – 9:40 am | MODELING THE PHARMACOKINETIC CHALLENGES OF ORAL SMALL MOLECULE DRUGS
Dr. Wei Zhu, Associate Principal Scientist, Merck
9:40 am – 10:15 am | FORMULATION STRATEGIES TO OVERCOME ORAL BIOAVAILABILITY CHALLENGES OF SMALL MOLECULE DRUGS
Mr. Stephen Tindal, Director, Science & Technology. Catalent Pharma Solutions
10:15 am – 10:30 am | BREAK
10:30 am – 11:30 am | AUDIENCE APPLIED LEARNING CHALLENGE- PART 1
AM Speakers
11:30 am – 1:00 pm | NETWORKING LUNCH & MEET THE EXPERTS
1:00 pm – 1:35 pm | CMC AND QUALITY CONSIDERATIONS
Mr. Jim Spavins, SVP, Pharm Sci (Ret.), Pfizer; Principal, Spavins Consulting LLC
1:35 pm – 2:10 pm | INSIGHTS AND STRATEGIES TO INCORPORATE PATIENT FOCUSED DESIGN
Dr. Cornell Stamoran, Founder, Catalent Institute
2:10 pm – 2:45 pm | STRATEGIES FOR PROGRESSING TO PHASE I FORMULATIONS TO IMPROVE YOUR SPEED TO AND SUCCESS IN THE CLINIC
Mr. Scott Herbig, Sr. Director, Drug Product Design (Ret.) Pfizer
2:45 pm – 3:00 pm | BREAK
3:00 pm – 4:00 pm | AUDIENCE APPLIED LEARNING CHALLENGE- PART 2
PM Speakers
4:00 pm | CONCLUDING REMARKS
Dr. Keith Horspool, VP, Pharmaceutics, Boehringer Ingelheim
Dr. Ronak Savla, Scientific Affairs Manager, Catalent Pharma Solutions